A Miami Veterans Affairs (VA) clinical site is now part of Longeveron’s Phase 2a clinical trial testing Lomecel-B — an investigational, bone marrow-derived, medicinal signaling cell (MSC) treatment — in patients with mild Alzheimer’s disease. The new clinical site was added following a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs. “After meeting the rigorous requirements of the VA, we are pleased to announce the addition of this particular Miami…
May 03, 2022May 3, 2022